By Dr. Michael Bennett, M.D.
Grand Rapids Women’s Health
Millions of American women suffer from a medical condition called heavy monthly bleeding (HMB). Many have periods so heavy they can limit daily activities, including work, childcare, exercise and managing household responsibilities.
Despite the significant impact of heavy periods, many women suffer in silence, according to “Living with HMB: A National Survey of 500 Women,” conducted online in June 2010 by Harris Interactive® on behalf of Ferring Pharmaceuticals. The survey found that:
• 92 percent of women were very frustrated by having HMB. Nearly two in three women (64 percent) said HMB has a significant negative impact on their social, leisure and physical activities.
• 47 percent could not adequately perform everyday household chores, 37 percent reported HMB negatively impacts their job, and 19 percent said it affects their ability to care for their family.
• HMB was also reported to negatively affect relationships. More than half (55 percent) reported it negatively affected their sex life. For three out of ten women, HMB had a negative impact on their relationship with their spouse or significant other.
• Remarkably, 37 percent had never talked to a doctor about their HMB. Those who haven’t consulted a healthcare professional think it is normal (42 percent) or think there is nothing their doctor can do about it (41 percent). Some women who haven’t discussed HMB with a healthcare professional (21 percent) were simply too embarrassed to talk about their condition.
As a physician, I encourage women to break their silence around HMB, and to talk to a healthcare professional about treatment options. Traditional treatments have been limited to pain relievers like ibuprofen and most hormonal contraceptives, which are not FDA-approved for HMB, as well as surgery such as endometrial ablation or hysterectomy.
Women also have another option: LYSTEDA™ (tranexamic acid) tablets, the only oral non-hormonal and non-surgical prescription medicine FDA-approved specifically to treat HMB. In clinical studies, LYSTEDA was shown to lower the amount of blood lost during monthly periods by about one-third.
LYSTEDA pills are taken only during the monthly period for up to five days, and have been shown to work across all treatment cycles studied and as early as the first cycle of use. LYSTEDA has not been studied in adolescents under age 18 with HMB.
For more information about HMB, talk to your doctor or visit www.lysteda.com.
This news release is sponsored by Ferring Pharmaceuticals Inc.